Objective-To determine whether serum levels of N-terminal (NT) pro-B-type natriuretic peptide (pro-BNP) are higher in patients with poorly compressible arteries (PCA) than in patients with peripheral artery disease (PAD) and control subjects without PCA or PAD. Methods and Results-Medial arterial calcification in the lower extremities results in PCA and may be associated with increased arterial stiffness and hemodynamic/myocardial stress. PCA was defined as having an ankle-brachial index Ͼ1.4 or an ankle blood pressure Ͼ255 mm Hg, whereas PAD was defined as having an ankle-brachial index Յ0.9. Study participants with PCA (nϭ100; aged 71Ϯ10 years; 70% men) and age-and sex-matched patients with PAD (nϭ300) were recruited from the noninvasive vascular laboratory. Age-and sex-matched controls (nϭ300) were identified from a community-based cohort and had no history of PAD. NT pro-BNP levels were approximately 2.5-fold higher in patients with PCA than in patients with PAD and approximately 4-fold higher than in age-and sex-matched controls. In multivariable regression analyses that adjusted for age, sex, smoking, hypertension, history of coronary heart disease/stroke, systolic blood pressure, and serum creatinine, NT pro-BNP levels remained significantly higher in patients with PCA than in patients with PAD and controls (PϽ0.001). Conclusion-Patients with medial arterial calcification and PCA have higher serum levels of NT pro-BNP than patients with PAD and controls, which is suggestive of an adverse hemodynamic milieu and increased risk for adverse cardiovascular outcomes. (Arterioscler Thromb Vasc Biol. 2011;31:197-202.)
M edial arterial calcification, first described by Monckeberg in 1902, 1 was initially thought to be a benign condition associated with aging. Subsequently, arterial calcification on radiographs of the feet was associated with increased cardiovascular and all-cause mortality, especially in patients with diabetes mellitus and chronic kidney disease. 2, 3 Medial arterial calcification typically affects the lower extremity arterial bed and results in poorly compressible arteries (PCA) and an artifactually high ankle blood pressure (BP) and ankle-brachial index (ABI). In the clinical setting, patients referred for noninvasive arterial evaluation are considered to have PCA if they have an ABI Ͼ1.4 or if the ankle BP is Ͼ255 mm Hg. In the National Health and Nutrition Examination Surveys (1999 to 2000 and 2001 to 2002), 1.4% of adults Ͼ40 years had an ABI Ͼ1.4, suggesting that at least 1.6 million individuals in the United States have medial arterial calcification. 4 Patients with an ABI Ͼ1.4 have similar or even greater cardiovascular and all-cause mortality when compared with patients with peripheral artery disease (PAD) (ABI Յ0.9). 5 Moreover, patients with PCA often have significant additional comorbidities, such as diabetes and chronic kidney disease, that add to the risk of adverse outcomes. 6, 7 A possible consequence of medial arterial calcification is increased arterial stiffness and, thereby, increased hemodynamic stress. 8, 9 Circulating levels of N-terminal (NT) pro-B-type natriuretic peptide (pro-BNP), a marker of hemodynamic stress, are elevated in patients with increased left ventricular mass, coronary heart disease (CHD), and PAD. 10 -12 Higher levels are also associated with increased cardiovascular mortality in asymptomatic individuals and in patients with CHD and PAD. [13] [14] [15] We hypothesized that patients with PCA have increased hemodynamic and myocardial stress that may lead to elevated NT pro-BNP levels. To test our hypothesis, we measured NT pro-BNP levels in patients with PCA and compared these with levels in ageand sex-matched patients with PAD and in age-and sex-matched control subjects without a history of PAD.
Methods
Patients with PCA and PAD were identified from the noninvasive vascular laboratory at Mayo Clinic, Rochester, Minn, between December 1, 2006 and December 1, 2008. A total of 107 patients with PCA and 513 patients with PAD were recruited during this period. The study was approved by the Mayo Clinic institutional review board, and informed consent was obtained from participants.
Noninvasive Arterial Evaluation
Patients suspected of having PAD are evaluated by measuring ABI at rest and 1 min postexercise and obtaining continuous-wave Doppler and pulse-volume recordings. The ABI is the ratio of BP at the ankle to BP at the arm. Normally Ͼ1.0, the ratio decreases in the setting of atherosclerosis of the leg arteries, leading to arterial narrowing. The ABI is measured in the supine position according to a standardized protocol. Appropriately sized BP cuffs are placed over each brachial artery and above each malleolus, and systolic BP is measured using a handheld 8.3-MHz Doppler probe. The higher of the 2 systolic brachial BP measurements is used to calculate the ABI. A standard treadmill test with a speed of 1 to 2 mile/h and a fixed grade of 10°with continuous electrocardiographic monitoring is performed to obtain postexercise ABI as well as pain-free and maximum walking distances. In patients with PAD, ankle systolic BP measurements decrease during low levels of workload 16 ; and postexercise ABI values are more sensitive for detecting PAD. 17 Patients were determined to have PAD if they had a resting or postexercise ABI Յ0.9. Patients with PCA were identified on the basis of having an ABI Ͼ1.4, an ankle BP Ͼ255 mm Hg, or nonreproducible ankle BP measurements.
We used International Classification of Diseases, Ninth Revision (ICD-9), code 428 (corresponding to the diagnosis of heart failure) to identify patients with heart failure within the time frame of 1 year, centered on the date of sample collection. The medical records of these patients were reviewed. The patients were excluded if they had an ejection fraction Ͻ50%, diastolic dysfunction grades 3 and 4, moderate or severe valvular abnormalities, or Framingham criteria for heart failure. Based on the previously described criteria, we excluded 7 patients with PCA and 25 patients with PAD, leaving 100 patients with PCA and 488 patients with PAD. For the 100 patients with PCA, we identified 300 age-and sex-matched cases with PAD.
Control Subjects
Controls without PAD or PCA belonged to the Prevalence of Asymptomatic Ventricular Dysfunction study, a random sample of Olmsted County residents Ն45 years (nϭ2042); these controls were identified using the resources of the Rochester Epidemiology Project. The design and selection criteria of the Prevalence of Asymptomatic Ventricular Dysfunction study, and the characteristics of the Olmsted County population, have been previously described. 18 -20 Participants gave written consent and underwent phlebotomy and echocardiography, including an evaluation for systolic and diastolic dysfunction. Of the 2,042 total participants, 45 were excluded because of presence of heart failure by Framingham criteria, 21 6 were excluded because of renal failure (serum creatinine Ͼ2.0 mg/ dL), 22, 23 and 46 were excluded for having an abnormal ABI or a history of PAD. From the remaining 1,945 participants, we identified 300 age-and sex-matched controls for the patients with PCA.
Patient Characteristics
Medical records were reviewed to ascertain age, sex, body mass index, systolic BP, diastolic BP, conventional cardiovascular risk factors (hypertension, diabetes, dyslipidemia, and smoking), history of CHD (ie, myocardial infarction, angina, coronary revascularization, or abnormal stress test or angiography result), cerebrovascular disease (ie, nonembolic ischemic stroke, Ͼ69% carotid artery stenosis, or history of carotid revascularization), and statin use. 24 In addition, serum creatinine and lipid levels closest to the date of recruitment were extracted from the medical record.
NT Pro-BNP Assay
NT pro-BNP levels were measured in serum using a commercially available electrochemiluminescence immunoassay on a commercially available platform (Modular Analytics E170). The intra-assay coefficient of variation values were 1.1% and 1.3% at 122.4 and 3,629 pg/mL, respectively; and the interassay coefficient of variation values were 3.1% and 1.8% at 120.8 and 3635 pg/mL, respectively.
Statistical Analyses
Statistical analyses were performed using computer software (SAS v 9.1.3). Continuous variables were expressed as meanϮSD or median (interquartile range), whereas dichotomous variables were expressed as percentages. To reduce skewness, serum NT pro-BNP levels were log transformed before regression analyses. Multivariable linear regression analyses were used to identify determinants of serum NT pro-BNP levels in each of the 3 study groups from among age, sex, body mass index, hypertension, diabetes, smoking, history of CHD or cerebrovascular disease, systolic BP, statin use, estimated glomerular filtration rate (eGFR), and serum creatinine. Subsequently, we performed multivariable regression analyses to compare NT pro-BNP levels in the study groups after adjustment for variables associated with NT pro-BNP levels. We also applied the manufacturer-recommended cutoff values of NT pro-BNP levels and those used in the ProBNP Investigation of Dyspnea in the Emergency Department and International Collaborative of NT-proBNP studies 25, 26 to calculate the percentages of patients who had elevated NT pro-BNP levels in each of the study groups.
Results
Characteristics of the 3 groups (PCA, age-and sex-matched PAD, and control) are shown in Table 1 . When compared with the age-and sex-matched PAD and control groups, patients with PCA had a greater prevalence of diabetes and a higher mean serum creatinine level. In multivariable regression models, variables associated with higher serum NT pro-BNP levels were as follows: PCA group, older age and higher serum creatinine level; PAD group, older age, lower total cholesterol level, and higher serum creatinine level; and controls, older age, female sex, history of CHD, and higher serum creatinine level ( Table 2) .
Patients in the PCA group had significantly higher levels of NT pro-BNP than in the age-and sex-matched PAD and control groups. Median (25%-75% interquartile range) NT pro-BNP levels were approximately 2.5-fold higher in the PCA group (417.0 [129.5-1,264.5] pg/mL) than in the PAD group (174.0 [73.4 -452.5] pg/mL) and approximately 4-fold higher than in the control group (112.7 [57.2-163.6] pg/mL) ( Figure 1 ). We compared NT pro-BNP levels in the 3 study groups using multivariable regression analyses that adjusted for the following variables: age, sex, body mass index, hypertension, diabetes, smoking, history of CHD/cerebrovascular disease, statin use, and serum creatinine. NT pro-BNP levels were significantly higher in the PCA group than in the age-and sex-matched PAD and control groups (PϽ0.001 for both) ( Table 3) .
Among patients with PCA, 59% had NT pro-BNP levels higher than the manufacturer-recommended cutoff values (Ͼ125 pg/mL for patients Ͻ75 years and Ͼ450 pg/mL for patients Ն75 years) compared with 44% in the PAD group and 28% in the control group. We also used the cutoff values suggested in the ProBNP Investigation of Dyspnea in the Emergency Department and International Collaborative of NT-proBNP studies, which consist of an age-independent rule-out value of 300 pg/mL and age-stratified rule-in values of 450, 900, and 1,800 pg/mL for ages Ͻ50, 50 to 75, and Ͼ75 years, respectively. 25, 26 Among patients with PCA, 56% had serum NT pro-BNP levels higher than the previously described rule-out value compared with 33% and 4% in the PAD and control groups, respectively. Moreover, 27% of patients with PCA had NT pro-BNP levels higher than the age-stratified rule-in values compared with 6% in the PAD group and 2% in the control group.
Discussion
Patients with PCA and an elevated ABI represent a distinct subset of PAD. Poor compressibility of the lower-extremity arteries is the result of medial arterial calcification, which typically circumferentially affects the arterial wall 27 and results in an artifactually high ankle BP and an elevated ABI (Ͼ1.4). Medial arterial calcification is associated with diabetes, chronic kidney disease, and an increased risk for adverse cardiovascular events and lower-extremity amputation. 27, 28 Most, but not all, patients with PCA have coexisting atherosclerosis, as evident by SI conversion factors: to convert serum creatinine to mol/L, multiply by 88.4; total and HDL cholesterol to mmol/L, by 0.0259; triglycerides to mmol/L, by 0.0113; and NT pro-BNP to pmol/L, by 0.118.
BMI indicates body mass index; CVD, cerebrovascular disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; SBP, systolic blood pressure.
*Data are given as number (percentage) of each group unless otherwise indicated. †Data are given as meanϮSD. ‡Data are given as median (25%-75% interquartile range). abnormal Doppler signals and/or low toe-brachial indexes. 29 In the present study, we report, for the first time to our knowledge, that serum NT pro-BNP levels are significantly higher in patients with PCA than in those with PAD and controls, even after adjustment for potential confounding variables. In patients with PCA, serum NT pro-BNP levels were approximately 2.5-fold higher than levels in age-and sex-matched patients with PAD and approximately 4-fold higher than levels in age-and sex-matched controls. Our findings suggest that patients with PCA have increased hemodynamic and myocardial stress that is greater than in patients with diffuse atherosclerosis (ie, patients with PAD who have an ABI Յ0.9).
Increased NT Pro-BNP Levels in the Setting of PAD
Patients with PAD had higher levels of NT pro-BNP than ageand sex-matched controls, although the difference was attenuated after adjustment for additional covariates. However, when all of the patients with PAD identified during the study period (nϭ488; aged 67Ϯ10 years; 64% men) were compared with age-and sex-matched controls from the community (nϭ976), the difference in median NT pro-BNP levels (139 versus 77 pg/mL) was highly significant (PϽ0.001) and independent of potential confounders (analyses not shown). These findings are consistent with the results of previous smaller studies 12, 30 and suggest greater hemodynamic stress in patients with PAD. Several factors may contribute to increased circulating levels of NT pro-BNP in patients with atherosclerotic vascular disease, including luminal narrowing and endothelial dysfunction, 27, 31, 32 leading to increased arterial resistance and cardiac afterload (Figure 2) . Also, such patients often have concomitant coronary atherosclerosis leading to myocardial ischemia, diastolic dysfunction, and increased left ventricular end-diastolic filling pressures. 8, 33, 34 The increased afterload, ventricular stiffness, and filling pressures will eventually lead to increased ventricular wall stress/tension and NT pro-BNP secretion. 35, 36 An additional mechanism may be renal vascular injury and impaired clearance of NT pro-BNP in the setting of diffuse atherosclerosis. 37
Increased Arterial Stiffness in Patients With Medial Arterial Calcification
Experimentally induced medial arterial calcification in rats results in increased arterial stiffness. 38 We are not aware of reports of direct measurement of arterial stiffness in patients with PCA; however, arterial stiffness is likely increased in patients with an ABI Ͼ1.4, leading to increased hemodynamic and myocardial stress. Indirect support for increased arterial stiffness in patients with PCA comes from a study 39 that found left ventricular mass to be higher in participants with PCA than in patients with PAD (ABI Յ0.9) and subjects without PAD (ABI: 0.9 to 1.4), independent of potential confounders. 39 The researchers also found ankle systolic BP to correlate with left ventricular mass. Our study extends these findings by demonstrating increased serum levels of NT pro-BNP, a humoral surrogate of increased arterial stiffness and hemodynamic stress, in patients with PCA. We did not find a correlation between ankle systolic BP and NT pro-BNP levels in our study (analyses not shown). Ankle BP measurements in patients with PCA are poorly reproducible and may not be reliable for use in statistical analyses. 
Peripheral Production of BNP
Many patients with PCA and PAD have NT pro-BNP levels similar to those in patients with heart failure. Because we excluded subjects with a history of overt heart failure based on medical record review, this raises the possibility that peripheral mechanisms may contribute to increased levels of NT pro-BNP. Kuhn et al 40 showed increased transcription and production of BNP in satellite cells within the ischemic skeletal muscle 3 days after femoral artery ligation in mice. The peripheral BNP production was also coupled with increased angiogenesis in the affected limb. 40 Another study 41 demonstrated impaired angiogenesis after hindlimb ischemia in mice lacking guanylyl cyclase-A, which plays a pivotal role in BNP signaling pathways. These recent studies suggest that increased production of peripheral BNP may be a response to stimulate angiogenesis in the ischemic skeletal muscles of patients with PCA and PAD.
Increased NT Pro-BNP Levels in Patients With PCA
Medial arterial calcification is distinct from the intimal calcification that occurs in atherosclerotic lesions; however, these 2 conditions may coexist, 42 leading to greater morbidity and mortality than any one condition by itself. Based on decreased toe-brachial indexes, one study 29 concluded that 60% of patients with medial arterial calcification have concomitant atherosclerosis. Of the 100 patients with PCA in our study, only 13 had normal lower-extremity arterial Doppler signals. However, NT pro-BNP levels were also elevated in this group (median, 274 pg/mL; mean, 911 pg/mL), suggesting that NT pro-BNP elevation in patients with PCA may be independent of concomitant atherosclerosis. In patients with PCA, the presence of medial arterial calcification may impede vascular regeneration, delay angiogenesis, and prolong ischemia in the affected skeletal muscles, resulting in an even greater stimulus for BNP production from satellite cells. We have summarized various pathways that may collectively increase serum NT pro-BNP levels in patients with PCA and PAD (Figure 2 ).
Clinical Implications
NT pro-BNP levels were predictive of mortality in patients with PAD in 2 previous studies 13, 14 ; we can speculate that NT pro-BNP is similarly predictive of adverse events in patients with PCA. However, the utility of NT pro-BNP as a predictor of mortality and adverse cardiovascular outcomes in patients with PCA needs further investigation. The potential angiogenic role of natriuretic peptides led Park et al 43 to evaluate the therapeutic effects of recombinant human atrial natriuretic peptide in 13 patients with PAD. A significant improvement in the ABI values, intermittent claudication, rest pain, and ulcer healing was noted in this small pilot study. 43 Whether pharmacological modulation of the natriuretic peptide system will have beneficial effects in patients with PCA or PAD needs further investigation, including randomized controlled trials.
Study Strengths and Limitations
To our knowledge, this study is the first to demonstrate elevated NT pro-BNP levels in patients with medial arterial calcification and PCA when compared with age-and sexmatched patients with PAD and controls. Our study identified patients with PCA and PAD from the noninvasive vascular laboratory of a tertiary care center, and some degree of referral bias may be present. The cross-sectional nature of our study precludes us from making inferences about the temporal relationship between onset of elevated NT pro-BNP levels and PCA or PAD. Not all PCA may be the result of medial arterial calcification, and we did not have foot radiographs available to confirm the presence of medial arterial calcification in patients with PCA.
In conclusion, serum NT pro-BNP levels were significantly higher in patients with medial arterial calcification and PCA than in patients with PAD and controls without a history of PAD. Nearly 60% of patients with PCA in our study had serum NT pro-BNP levels higher than the manufacturer-recommended levels to rule out heart failure. Although greater hemodynamic and myocardial stress as the result of increased arterial stiffness is a plausible mechanism underlying our findings, BNP secretion by ischemic skeletal muscles has been recently reported 40 and may also be operative. Whether NT pro-BNP levels predict mortality and adverse cardiovascular outcomes in patients with PCA needs confirmation in future studies. Finally, the therapeutic potential of BNP analogues in patients with PCA and PAD may be the subject of investigation in future clinical trials.
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